title: Transdermal rotigotine in restless legs syndrome: impulse control disorders.
abstract: Detailed case reports have confirmed that the dopamine agonist rotigotine, marketed in transdermal patches, exposes patients to the risk of impulse control disorders, even at the doses recommended for restless legs syndrome. In most cases, the symptoms regressed after reducing the dose or discontinuing the drug.
mesh_terms: D000279:Administration, Cutaneous; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced / Q000523:psychology; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D012148:Restless Legs Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012307:Risk Factors; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage* / Q000009:adverse effects; D013876:Thiophenes / Q000008:administration & dosage* / Q000009:adverse effects; D057968:Transdermal Patch; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine